Mulligan BioCapital
VC Fund
Hamburg, Germany
Mulligan BioCapital is an investment firm dedicated to the life sciences with a specific focus on biotechnology with health care applications.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Mulligan BioCapital invests in
Stages Mulligan BioCapital invests in
Countries Mulligan BioCapital invests in
Investment Focus
Industry
- Medical 3 (60%)
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Genetics 1 (20%)
- Biopharma 1 (20%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Series C 1 (20%)
- Funding Round 1 (20%)
Country
- Germany 3 (60%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DIREVO Industrial Biotechnology
|
DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaderssuch as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors. | $16.8M / Series C / Oct 18, 2007 | |
Spinal Cord Therapeutics GmbH
|
Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system. | $14M / Series A / Sep 19, 2005 | |
4-Antibody AG
|
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also developspreclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.4-Antibody AG was founded in 2002 and is based in Basel, Switzerland. | $3.3M / Seed / Mar 17, 2004 | |
Cardion
|
Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen. | $12.6M / Sep 23, 2002 | |
|
DIREVO Industrial Biotechnology
|
DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaderssuch as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors. | $9.7M / Series A / Dec 18, 2000 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Mulligan BioCapital invest in?
Mulligan BioCapital invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Mulligan BioCapital last invest?
The most recent investment recorded for Mulligan BioCapital closed in Oct 2007. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
